Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study
2016 ASTRO Annual Meeting
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)
Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)